

# **THERAPEUTIC CLASS REPORT: WILL NEXT GENERATION ORAL ANTICOAGULANTS REPLACE WARFARIN AS MAINSTAY THERAPY**

<https://marketpublishers.com/r/TA5FA78C70BEN.html>

Date: August 2011

Pages: 100

Price: US\$ 2,000.00 (Single User License)

ID: TA5FA78C70BEN

## **Abstracts**

**WILL WARFARIN CONTINUE AS A MAINSTAY TREATMENT IN THE ERA OF NEXT GENERATION ORAL ANTICOAGULANTS**

Pradaxa: With first mover advantage, Will it be the Leader in SPAF?

Xarelto: Is it the future mainstay anticoagulant therapy?

Eliquis and Edoxaban: Would they be able to differentiate enough?

In the coming months, there are major regulatory and clinical milestones with regard to the new generation of oral anticoagulants (Pradaxa, Xarelto, Eliquis and Edoxaban), which will have wide ranging impact on the treatment paradigm in several therapeutic areas encompassing - stroke prevention in atrial fibrillation / DVT Treatment / VTE prevention in medically ill patients and Acute coronary syndrome.

This therapy class report analyses the practical issues in the adoption of new generation anticoagulants, major upcoming milestones, clinical trial design/data and cost-effectiveness of recently launched and upcoming molecules. This report will provide insightful information about the performance of molecules in oral anticoagulation arena in all the indications (SPAF, VTE, ACS) and the way these newer drugs will be positioned to garner the benefits against Aspirin/Warfarin/Lovenox are discussed.

## Contents

### 1. ANTICOAGULANTS MARKET

Market size and Segmentation – By Drugs and Indications

Goals (Duration) of Current anticoagulant therapy in different indications

New generation anticoagulants pipeline

Major Upcoming Milestones

Estimated launch timelines for new generation anticoagulants– Indication wise

Characteristic of Ideal anticoagulant

Factor Xa Vs. Direct Thrombin inhibitor

### 2. STROKE PREVENTION IN ATRIAL FIBRILLATION

The Current Market Dynamics- Geography wise prevalence of SPAF and treatment paradigm of anticoagulation therapy in SPAF

The need for new generation anticoagulants

Does higher unmet need prevail in high risk (CHADS2 score) patients or low risk patients?

Experts view on the hurdles to the adoption of new generation anticoagulants in SPAF

Factors that will influence the choice of anticoagulation therapy in Atrial Fibrillation – Regulatory and Clinical

Patient's history of stroke and bleeding risk factors impacting treatment decision

Regulatory Scenario – Medicare Shared Saving program to be implemented in 2012

Reimbursement status of PT/INR monitoring for warfarin in major countries

Physician's Experience and cost effectiveness

Warfarin Genotype testing, its regulatory approval and its reimbursement

Warfarin continues to hold itself strong against Pradaxa – Will the entry of Xarelto / Eliquis / Edoxaban change the scenario?

Clinical data comparison of AVERROES, RELY and ROCKET AF Studies and our analysis on each clinical data

Baseline and Trial Design comparisons – RELY, ROCKET AF AND ARISTOTLE

Overall Efficacy and Safety comparison – ROCKET, RELY AND AVERROES

Efficacy and safety comparison in high risk patient's population

Clinical data analysis from ROCKET- AF detail data

AVERROES trial rationale and results – No commercial implications

What to expect from the detailed data of ARISTOTLE (Eliquis) at ESC?

FDA Advisory Committee's – The Key Questions on Xarelto for approval in SPAF - Will the Label be comparable to Pradaxa?

Universal antidote for novel oral anticoagulants

The Future Mainstay Treatment In SPAF - Xarelto Or Pradaxa Or Eliquis

### **3. ROLE OF NEW GENERATION ORAL ANTICOAGULANTS IN VTE PREVENTION IN ORTHOPEDIC SURGERY**

Prevalence of VTE after Total Hip Replacement Surgery / Total Knee Replacement Surgery

The need and importance for extended prophylaxis and current limitations

Clinical data comparison – Xarelto, Eliquis and Pradaxa

### **4. ROLE OF NEW GENERATION ORAL ANTICOAGULANTS IN VTE PREVENTION IN MEDICALLY ILL PATIENTS**

Market segmentation based on Illness

Risk/Incidence of DVT and Fatal PE in different categories of Medically Ill Patients

Incidence Of DVT In Orthopedic Surgery Vs. Acute Medically Ill Patients

VTE Prevention in Cancer Patients – VTE incidence rates in different types of cancer

Ongoing clinical studies

Xarelto – Review of MAGELLAN study

Semuloparin - Clinical data comparison Of VTE prophylaxis in cancer Patients

### **5. ROLE OF NEW GENERATION ORAL ANTICOAGULANTS - VTE TREATMENT**

New Generation anticoagulants will expand the DVT treatment opportunity manifold

Pradaxa - RECOVER study

Eliquis - BOTTICELLI Study and AMPLIFY study

Xarelto – EINSTEIN DVT study

Xarelto – EINSTEIN EXT study

Xarelto – Other Ongoing studies

Edoxaban – HOKUSAI study

Clinical data comparison from DVT treatment studies

### **6. FACTOR XA INHIBITORS- DO THEY HAVE POTENTIAL TO BE AN IDEAL ANTICOAGULANT FOR SECONDARY PREVENTION OF ACS?**

Historically anticoagulant have failed to show a positive risk-reward profile in ACS -

Xarelto is likely to be an exception

Clinical data comparison of Anticoagulant as add on to current ACS treatment vs.

Newer Antiplatelets agent

Upcoming clinical data newsflow which has potential to change market dynamics

## **7. WHO IS BETTER POSITIONED IN EARLY STAGE FACTOR Xa INHIBITORS? – YM150**

LY517717

Eribaxaban

Betrixaban

TAK-442

## **8. HOW THE NEXT GENERATION ORAL ANTICOAGULANTS WOULD STACK UP?**

### **ANNEXURES**

Goals of Anticoagulation therapy

Current Anticoagulation - Market Segmentation by drugs and Indication

Characteristics of an Ideal Anticoagulant

New Generation Anticoagulant Pipeline

Clinical profile

a) Rivaroxaban

b) Dabigatran

c) Apixaban

d) Edoxaban

e) Betrixaban

f) Other Early Stage Compounds- YM 150, TAK 442

Preclinical profile of Eliquis, Pradaxa and Xarelto

Pharmacokinetic/dynamic comparison of Factor Xa inhibitors/direct Thrombin inhibitor vs. Warfarin

Clinical Data comparison of major anticoagulants in VTE prevention

Prevalence of VTE after Total Hip Replacement Surgery / Total Knee Replacement Surgery

VTE Incidence in patients taking prophylaxis Vs. Those not taking Prophylaxis post Discharge

Rate of Fatal PE Emboli and DVT In different categories of Medically Ill Patients

Reported VTE incidences In Various types of Cancer

Comparison of Clinical data from Trials – Prevention of VTE in cancer Patients

Clinical Data comparison major anticoagulants in DVT treatment

Clinical Data comparison major anticoagulants in ACS Liver Toxicity

Long term safety concern: Liver Toxicity

Assessment of Bleeding Risk

Clinical Data comparison - Stroke Prevention In AF Studies (Edoxaban, Betrixaban, Pradaxa, Exanta, Warfarin, aspirin, Eliquis, Xarelto)

Stroke Prevention in Atrial Fibrillation – Market segmentation by drug usage srosivdA  
PMNext Generation Oral Anticoagulants / 05

Baseline Characteristics Comparison Of Pivotal Trials In SPAF – ROCKET, RELY, ARISTOTLE and AVERROES

Reimbursement status of PT/INR monitoring for warfarin in major countries

Estimated launch timelines for new generation anticoagulants– Indication wise

PhIII Trial Design of late stage Factor Xa Inhibitors for Stroke Prevention in AF

Mortality Rate in Atrial Fibrillation – By Gender and Age

Stroke Rate Per 100 Patient Years Increases Substantially With CHADS2 Score

Reported VTE Incidences In Various Cancer

Incidence Of DVT In Orthopedic Surgery Vs. Acute Medically Ill Patients

Risk / Incidence of DVT and Fatal PE in different categories of Medically Ill Patients

Ongoing Clinical trials in ACS, whose outcome will have significant implications on the treatment paradigm and market potential

Clinical data comparison – VTE Prevention in Medically Ill Patients

Upcoming Milestones – New Generation Anticoagulants

## I would like to order

Product name: THERAPEUTIC CLASS REPORT: WILL NEXT GENERATION ORAL  
ANTICOAGULANTS REPLACE WARFARIN AS MAINSTAY THERAPY

Product link: <https://marketpublishers.com/r/TA5FA78C70BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer  
Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click  
button on product page <https://marketpublishers.com/r/TA5FA78C70BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form  
below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms  
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970

